ADAM17 and dry eye syndrome: For example, abatacept treatment reduces the number of activated circulating Tfh cells, thereby contributing to the attenuation of Tfh cell-dependent B cell hyperactivity in SS (134); disintegrin and metalloproteinase-17 (ADAM17) inhibitors abrogate CXCL1/CXCR2 interactions to block the inflammatory response in SS (135); miR-744-5p may be a potential therapeutic target to ameliorate ocular inflammation in SS patients with dry eye (136); and poly (ADP-ribose) polymerase family member 9 (PARP-9) is a regulator of immune cell infiltration during SS progression (137).